bioavailability is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
During Alice in Chains' hiatus, reports of Staley's addiction began to gain widespread circulation in fan and media communities, in part due to changes in his physical condition brought on by prolonged heroin abuse. Alice in Chains regrouped to record Alice in Chains, sometimes referred to as "Tripod" due to the cover featuring a three-legged dog, which was released in November 1995. The album debuted at the top of the U.S. charts, and has since been awarded—along with Facelift and Jar of Flies—double platinum status. With the exceptions of "Grind", "Heaven Beside You", and "Over Now", the lyrics were all written by Staley, making this album his greatest lyrical contribution to the band's catalog. To accompany the album, the band released a home video, The Nona Tapes, but the band lapsed again, failing to complete tours planned in support of the album. When asked about the frustration of not touring to support the record, Cantrell provided some insight into how Staley's addictions led to tensions within the band: "Very frustrating, but we stuck it out. We rode the good times together, and we stuck together through the hard times. We never stabbed each other in the back and spilled our guts and [did] that kind of bullshit that you see happen a lot." "Drugs worked for me for years", Staley told Rolling Stone in February 1996, "and now they're turning against me, now I'm walking through hell and this sucks. I didn't want my fans to think that heroin was cool. But then I've had fans come up to me and give me the thumbs up, telling me they're high.
== History == Biomatrica was founded by scientists, Judy Müller-Cohn, PhD, and Rolf Müller, PhD, in 2004. Prior to founding Biomatrica, both had worked many years in San Diego's biotechnology industry. Müller-Cohn had previously worked at Digital Gene Technologies and Mycogen/ Dow Agrosciences, whilst Müller had worked on the HIV Core Program Project Grant at San Diego's Scripps Research Institute. Biomatrica initially developed ambient temperature storage reagents for DNA and RNA. The company's core technology was inspired by the phenomenon of anhydrobiosis, the ability of some organisms to hibernate in a desiccated state during dry periods, and then reanimate upon contact with water. Focusing on microscopic, desert-dwelling creatures called Tardigrades, which undergo anhydrobiosis for up to 120 years, Biomatrica identified how to chemically mimic the mechanism of anhydrobiosis. Following stabilization at room temperature with Biomatrica's chemical reagents, biological specimens could be rehydrated for subsequent studies with the addition of a few drops of water. Since 2012, the company has become increasingly focused on its pre-analytic collection and assay stabilization service businesses described below. In October 2018 Biomatrica was acquired by the Madison, Wisconsin-based molecular diagnostics and cancer screening company Exact Sciences Corporation for $20 million.
== Additional references == Bodenhamer, David J; Barrows, Robert G, eds. (1994). The Encyclopedia of Indianapolis. Bloomington and Indianapolis: Indiana University Press. ISBN 978-0-253-31222-8. Kahn, E. J. (1975). All In A Century: The First 100 Years of Eli Lilly and Company. West Cornwall, CT: Eli Lilly and Company. OCLC 5288809. Podczeck, Fridrun; Jones, Brian E. (2004). Pharmaceutical Capsules. Chicago: Pharmaceutical Press. ISBN 978-0-85369-568-4. Price, Nelson (1997). Indiana Legends: Famous Hoosiers From Johnny Appleseed to David Letterman. Indianapolis: Guild Press of Indiana. ISBN 978-1-57860-006-9. Taylor Jr., Robert M.; Stevens, Errol Wayne; Ponder, Mary Ann; Brockman, Paul (1989). Indiana: A New Historical Guide. Indianapolis: Indiana Historical Society. p. 481. ISBN 978-0-87195-048-2. Tobias, Randall; Tobias, Todd (2003). Put the Moose on the Table: Lessons in Leadership from a CEO's Journey through Business and Life. Indiana University Press. ISBN 978-0-253-11011-4. Weintraut, Linda; Nolan, Jane R. "The Secret Life of Building 314". Traces of Indiana and Midwestern History. 8 (3). Indianapolis: Indiana Historical Society: 16–27.
Sources: en.wikipedia.org
It appears that this gene loss has happened several times independently in evolutionary separated groups of animals. Lack of ghrelin and MBOAT4 may be relevant to the way that these reptiles can live at a low energy demand for months or years. Their fat stores are used at a low level. The presence of many mutations in genes for aspects of mitochondrial function in these animals may also be involved in their reduced energy demand.
Several additional studies have found that eflornithine in combination with other compounds decreases the carcinogen concentrations of ethylnitrosourea, dimethylhydrazine, azoxymethane, methylnitrosourea, and hydroxybutylnitrosamine in the brain, spinal cord, intestine, mammary gland, and urinary bladder.
Subdermal hematoma (under the skin) Intramuscular hematoma (inside muscle tissue) Skull/brain: Subgaleal hematoma – between the galea aponeurosis and periosteum Cephalohematoma – between the periosteum and skull. Commonly caused by vacuum delivery and vertex delivery. Epidural hematoma – between the skull and dura mater Subdural hematoma – between the dura mater and arachnoid mater Subarachnoid hematoma – between the arachnoid mater and pia mater (the subarachnoid space) Othematoma – between the skin and the layers of cartilage of the ear Breast hematoma (breast) Perichondral hematoma (ear) Perianal hematoma (anus) Subungual hematoma (nail) Rectus sheath hematoma Genital hematoma
Sources: en.wikipedia.org
La Niña events have been observed for hundreds of years, and occurred on a regular basis during the early parts of both the 17th and 19th centuries. Since the start of the 20th century, La Niña events have occurred during the following years:
Abraham White (March 8, 1908 – February 14, 1980) was a professor of biochemistry who made several important discoveries in his field during the middle of the 20th century and helped write a foundational textbook, Principles of Biochemistry, which was published in 1954. The book went through six editions before its authors retired. White was born in Cleveland, Ohio, to Morris and Lena White. His siblings were Essie and Julius ("Jay"). When he was about one year old, his family moved to Lafayette, Colorado, and then later to Denver. White earned his bachelor's and master's degrees at the University of Colorado and a Ph.D. degree in Physiological Chemistry at the University of Michigan in the laboratory of Howard B. Lewis. This was followed by a postdoctoral fellowship at the Yale School of Medicine with Hubert Bradford Vickery at the Connecticut Agricultural Experiment Station.
Caffeine consumption during pregnancy is associated with increased risk of pregnancy loss and increased risk of low birth weight, defined as below 2500 grams (5.5 pounds). The European Food Safety Authority and the American Congress of Obstetricians and Gynecologists concur that habitual caffeine consumption up to 200 mg per day by pregnant women does not give rise to safety concerns for the fetus. The United Kingdom Food Standards Agency had recommended that pregnant women should limit their caffeine intake to less than 300 mg of caffeine a day, but in 2009 revised that downward to less than 200 mg of caffeine a day. High doses of caffeine intake during pregnancy may increase the risk of miscarriage and some major negative pregnancy outcomes, such as stillbirth or low birth weight. A 2020 review called into question the safe levels proposed by the European Food Safety Authority, the American Congress of Obstetricians and Gynecologists, the National Health Service, and the Dietary Guidelines for Americans. It found that the current scientific evidence does not support moderate caffeine consumption during pregnancy as safe, and advised pregnant women and women contemplating pregnancy to avoid caffeine.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.